Plecanatide
Plecanatide is an FDA-approved guanylate cyclase-C agonist. Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine.
For research use only.
Key Facts
- CAS
- 467426-54-6
- Molecular Weight (MW)
- 1681.9 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- oral
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Orally administered uroguanylin analog approved for chronic idiopathic constipation and for irritable bowel syndrome with constipation. Like linaclotide it acts locally on intestinal epithelium with minimal systemic exposure.
Peptide Library's Plecanatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- oral
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Plecanatide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C65H104N18O26S4 |
|---|---|
| Molecular weight | 1681.9 g/mol |
| CAS number | 467426-54-6 |
| PubChem CID | 70693500 |
| FDA UNII | 7IK8Z952OK |
| ChEMBL | CHEMBL2103867 |
| DrugBank | DB13170 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine. Receptor activation raises cyclic GMP, driving chloride and bicarbonate secretion into the lumen and increasing intestinal fluid and transit.
Studies
- Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- Plecanatide for the treatment of constipation-predominant irritable bowel syndrome
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
- Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome
- Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome
Regulatory & research status
Plecanatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Plecanatide: frequently asked questions
What is Plecanatide?
Orally administered uroguanylin analog approved for chronic idiopathic constipation and for irritable bowel syndrome with constipation. Like linaclotide it acts locally on intestinal epithelium with minimal systemic exposure.
How does Plecanatide work?
Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine. Receptor activation raises cyclic GMP, driving chloride and bicarbonate secretion into the lumen and increasing intestinal fluid and transit.
Is Plecanatide FDA approved?
Yes. Plecanatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Plecanatide?
Compounds most often compared with Plecanatide include Teduglutide, Linaclotide, Larazotide and Secretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial — Drugs, 2025External reference
- Plecanatide for the treatment of constipation-predominant irritable bowel syndrome — Expert Rev Gastroenterol Hepatol, 2020External reference
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis — Lancet Gastroenterol Hepatol, 2019External reference
- Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome — Am J Med, 2019External reference
- Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome — Expert Opin Pharmacother, 2018External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Plecanatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Plecanatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →